Company Overview

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicine therapies for the treatment of addiction and substance use disorders, primarily alcohol use disorder (AUD). The company operates within the biotechnology and pharmaceutical research industry and is publicly traded on the Nasdaq under the ticker ADIL. Its core strategy is to develop genetically targeted therapeutics that improve efficacy and safety by matching treatments to specific patient subpopulations.

The company’s primary product candidate is AD04, an investigational treatment for AUD designed to target patients with specific genetic markers associated with the serotonin-3 (5-HT3) receptor pathway. Adial’s positioning centers on applying pharmacogenomics to large, underserved addiction markets, differentiating it from traditional addiction-treatment approaches that typically do not incorporate genetic stratification. Adial Pharmaceuticals was founded in 2010 by Bankole A. Johnson, MD, PhD, and has since evolved from early academic research into a publicly listed company advancing late-stage clinical development programs.

Business Operations

Adial’s operations are centered on drug development, clinical trials, and regulatory strategy, rather than commercial manufacturing or product sales. The company currently does not generate material commercial revenue and instead relies on equity financing and strategic capital raises to fund research and development activities. Its principal operating focus is the clinical advancement of AD04, including Phase 3 trial preparation, regulatory engagement, and intellectual property management.

Operational activities are primarily based in the United States, with clinical trials conducted through third-party research organizations and clinical sites. Adial controls its proprietary genetic and clinical data related to AUD treatment response and maintains a portfolio of patents covering methods of treatment and patient selection. As of publicly available filings, the company does not report material revenue-generating subsidiaries or joint ventures; any additional pipeline assets beyond AD04 have limited publicly disclosed development activity, and available public sources are inconclusive regarding their clinical stage progression.

Strategic Position & Investments

Adial’s strategic direction emphasizes precision medicine in addiction treatment, with a near-term focus on advancing AD04 toward potential regulatory approval. Growth initiatives are concentrated on completing clinical development milestones, strengthening intellectual property protections, and exploring strategic partnerships that could support commercialization or further development. The company has highlighted the potential to apply its genetic targeting platform to other substance use disorders, though these efforts remain exploratory.

The company has not announced major acquisitions in recent public disclosures, and its investment activity is largely internal, directed toward clinical research and regulatory readiness. While Adial has referenced broader applications of its pharmacogenomic approach, publicly available sources indicate that AD04 remains the dominant asset. Information on additional portfolio companies, material equity investments, or late-stage pipeline diversification is limited, and data is inconclusive based on available public sources.

Geographic Footprint

Adial Pharmaceuticals is headquartered in the United States, with corporate offices in Virginia. Its operational footprint is primarily domestic, reflecting its focus on U.S.-based clinical trials, regulatory engagement with the U.S. Food and Drug Administration (FDA), and investor relations activities. International operations are limited and largely indirect, conducted through clinical research collaborations when applicable.

While the company positions its therapies for global relevance due to the worldwide prevalence of alcohol use disorder, it does not currently report significant commercial or operational infrastructure outside North America. Any future international expansion is expected to be contingent on regulatory approvals and strategic partnerships, and there is no verified disclosure of substantial overseas assets or subsidiaries.

Leadership & Governance

Adial Pharmaceuticals was founded by Bankole A. Johnson, MD, PhD, a recognized researcher in addiction medicine, whose scientific work underpins the company’s precision medicine approach. The current leadership team brings experience in biotechnology development, clinical research, and public company governance, with a strategic emphasis on disciplined capital management and data-driven clinical execution.

Key executives include:

• Cary Claiborne, MD – President and Chief Executive Officer
• Bankole A. Johnson, MD, PhD – Founder and Chairman of the Board
• Chris Lynch – Chief Financial Officer (public disclosures indicate this role; exact appointment timing varies across sources)
• Kathleen M. Jagodzinski – Chief Operating Officer (role and scope reported in company filings)

The leadership philosophy emphasizes advancing scientifically validated therapies for addiction through rigorous clinical development and regulatory alignment. Where executive roles or tenure details vary across public disclosures, data is inconclusive based on available public sources.